NCT02716987View on ClinicalTrials.gov

Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 21, 2016

Primary Completion Date

August 30, 2016

Study Completion Date

August 30, 2016

Conditions
Healthy
Interventions
DRUG

TAK-831

TAK-831 oral suspension.

DRUG

[18F]PGM299

\[18F\]PGM299 injection

Trial Locations (1)

Unknown

London

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Neurocrine Biosciences

INDUSTRY